Manufacturers, industry groups comment on FDA’s control over nitrosamines in drug products
The FDA has received comments from manufacturers and other industry players on how best to tackle impurities known as nitrosamines in drugs.
In May, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
